Evidence map›Paper›PMID 25733807›Full record

ArticleDrug design, development and therapy2015

Anesthetic drug midazolam inhibits cardiac human ether-à-go-go-related gene channels: mode of action.

Nadine Vonderlin, Fathima Fischer, Edgar Zitron, Claudia Seyler, Daniel Scherer, Dierk Thomas, Hugo A Katus, Eberhard P Scholz

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. A Proline Derivative-Enriched Fraction fromInternational journal of molecular sciences · 2020
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nadine VonderlinDepartment of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.
Fathima FischerDepartment of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.
Edgar ZitronDepartment of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany ; German Centre for Cardiovascular Research, Partner Site Heidelberg/Mannheim, Heidelberg, Germany.
Claudia SeylerDepartment of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.
Daniel SchererDepartment of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.
Dierk ThomasDepartment of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany ; German Centre for Cardiovascular Research, Partner Site Heidelberg/Mannheim, Heidelberg, Germany.
Hugo A KatusDepartment of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany ; German Centre for Cardiovascular Research, Partner Site Heidelberg/Mannheim, Heidelberg, Germany.
Eberhard P ScholzDepartment of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.
University Hospital Heidelberg · DEHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Midazolam is a short-acting benzodiazepine that is in wide clinical use as an anxiolytic, sedative, hypnotic, and anticonvulsant. Midazolam has been shown to inhibit ion channels, including calcium and potassium channels. So far, the effects of midazolam on cardiac human ether-à-go-go-related gene (hERG) channels have not been analyzed. The inhibitory effects of midazolam on heterologously expressed hERG channels were analyzed in Xenopus oocytes using the double-electrode voltage clamp technique. We found that midazolam inhibits hERG channels in a concentration-dependent manner, yielding an IC50 of 170 μM in Xenopus oocytes. When analyzed in a HEK 293 cell line using the patch-clamp technique, the IC50 was 13.6 μM. Midazolam resulted in a small negative shift of the activation curve of hERG channels. However, steady-state inactivation was not significantly affected. We further show that inhibition is state-dependent, occurring within the open and inactivated but not in the closed state. There was no frequency dependence of block. Using the hERG pore mutants F656A and Y652A we provide evidence that midazolam uses a classical binding site within the channel pore. Analyzing the subacute effects of midazolam on hERG channel trafficking, we further found that midazolam does not affect channel surface expression. Taken together, we show that the anesthetic midazolam is a low-affinity inhibitor of cardiac hERG channels without additional effects on channel surface expression. These data add to the current understanding of the pharmacological profile of the anesthetic midazolam.

Indexed as

AnestheticsAnimalsDose-Response Relationship, DrugEther-A-Go-Go Potassium ChannelsHEK293 CellsHumansMidazolamStructure-Activity RelationshipXenopusAnestheticsEther-A-Go-Go Potassium ChannelsMidazolamanestheticshuman ether-à-go-go-related genemidazolampotassium channels

Identifiers

PMID25733807
PMCPMC4338257
OpenAlexW1980872446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.